Literature DB >> 2938091

[Treatment of septicemia and endocarditis with pefloxacine. 15 cases].

M Wolff, B Pangon, B Regnier, E Rouveix, J Bauchet, F Vachon.   

Abstract

The therapeutic effectiveness of pefloxacin was evaluated in 15 patients admitted to an intensive care unit and suffering from septicaemia or endocarditis. Seven of these patients had a focal infection (acute anterior mediastinitis or epiduritis). Pefloxacin was combined with an aminoglycoside in 13 cases and with rifampicin in 1 case. Blood cultures became or remained negative in all patients. The associated focus of infection was sterilized in 5 patients; a pefloxacin-resistant pathogen was subsequently isolated in 2 other patients. Three patients died some time after the infectious episode. The minimum inhibitory concentration of pefloxacin ranged from 0.25 to 2 mg/l. The bactericidal activity of the serum at peak concentration was greater than or equal to 1/8 in all cases and greater than or equal to 1/32 in 10 cases. No resistant mutants were selected during treatment. However, 8 strains of a species different from that of the initial pathogen were isolated from a site other than the primary focus. Pefloxacin can therefore be used successfully in the treatment of systemic infections, but close monitoring of bacterial ecology is required.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2938091

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  3 in total

1.  Treatment of respiratory tract infections with pefloxacin in critically ill patients hospitalized in a surgical intensive care unit.

Authors:  D M Boland; W C van Gestel; D M MacLaren; D de Jong
Journal:  Pharm Weekbl Sci       Date:  1987-12-11

Review 2.  Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J P Gonzalez; J M Henwood
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

3.  Steady-state levels of pefloxacin and its metabolites in patients with severe renal impairment.

Authors:  P Jungers; D Ganeval; T Hannedouche; B Prieur; G Montay
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.